#Anthony Fauci, MD

Last year, the federal agency invested nearly $300 million in the search for HIV cure therapies.

The injectable hormone was approved to treat excess abdominal fat in those with antiretroviral-associated lipodystrophy.

Calling all U.S. cisgender gay and bi men and trans and gender nonconforming people at risk for the virus.

Expect “Ending the Epidemics realness,” disruptive innovation and Mother Elektra at #2019USCA.

“We’re very happy,” says PAC’s Murray Penner. But he’d like the federal agency to take these additional steps.

An NIH-sponsored peer-recruitment study is part of a larger push to figure out how to drive up the viral suppression rate in the U.S.

The Mosaico study will enroll gay and bisexual men and transgender people at significant risk for the virus.

Federal researchers describe two paths to a vaccine—and one of them uses high-tech computers to design a vaccine candidate!

The CDC holds the patents to Truvada-as-PrEP, but hasn’t asked for a dime in royalties from Gilead. This is costing taxpayers billions. Why?

Broad details emerge, such as targeting the HIV hot spots that, when combined, account for 50 percent of new HIV cases.

The new federal initiative will work with existing research programs in eight cities.

The newly released PARTNER2 study documented 77,000 condomless anal sex acts between mixed-HIV-status men; Opposites Attract had 12,000.

Promising news on the prevention front

At stake in amfAR’s civil war is the nonprofit’s quest to find a cure for HIV.

Courting controversy, the NIH considers a shift away from the development of new vaginal or rectal-based HIV prevention products.

A statement from the National Institutes of Health on World AIDS Day 2017.